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Abstract 
Patenting genes first developed through US case law in the 1980s. Shortly after Europe 
??????????????????????????????????????????????????????????????????????????????????????????????
the EU started creating a directive aimed to unify how its member states administered 
biotechnical patents. The aim of the directive was to facilitate trade and to hinder biotechnical 
industries fleeing Europe in favor of countries with more generous patent legislation. In 
????????? ???? ??????? ???????? ????????? ????? ?????? ??????? ???? ?????? ??? gene patents and the 
directive merely enforced minor adjustments to the member states legislation.  
Since the commencement of gene patents a debate over its ethics have raged. Many 
representatives of different sectors in society are largely opposed to gene patents. This debate 
has now extended over 30 years and it has become clear that patenting genes is a subject 
which is far from settled. The Myriad case in the US is a clear demonstration of the steady 
insubordination of gene patents. Beside the ethical arguments there are also legitimate 
technical judicial arguments which exclude genes from being patentable on the basis that 
genes are mere discoveries and thus should not be patentable.  
The scope of rights conferred to gene patents is another subject which has voiced a strong 
debate. The realm of protection for gene patents was directly modeled after the protection 
assigned to chemical molecules; namely absolute product protection. The absolute product 
protection allows the patentee to claim infringement on all potential uses of the gene, 
independent of what industrial application has been stated on the patent application. This is a 
very broad form of patent which has been criticized for deviate from the patent balance since 
the scope of protection is not necessarily in relation to the scientific achievement.  
When gene patenting was first allowed patent offices were flooded with applications which 
has now lead to that 20 % of the human genome is patented. Within the US and the EPO case 
law and guidelines have been presented which limit the patentability of genes. This, along 
with the presentation of the HGS project, has resulted in a diminished number of patent 
applications which has thus haltered the patenting rate.  
Independent of the raised criteria for patent applications the scope of protection remains 
broad.  The Monsanto case from 2010 does clarify a limitation, namely that the gene has to be 
functional for an infringement of patent rights to have taken place. It is not enough that the 
 6 
gene could be purified from the product and inserted into another plant and herein be 
functional again, the gene has to serve a purpose in the current state for the scope of patent 
rights to include this situation. 
In the aftermath of the Myriad case the US government hired Duke University to produce a 
report on gene patents and efficiency. This report clarifies that gene patents are not always the 
most efficient solution to ensure technical developments. To remove gene patents as a whole 
is not a realistic solution but, as the Duke report indicates, it may be more efficient to segment 
different types of genes with varying scopes of protection in order to ensure steady advances 
within biotechnology.  
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Abbreviations 
ACLU  American Civil Liberties Union 
DNA  Deoxyribonucleic acid 
ECJ  European Court of Justice 
EPC  European Patent convention 
EPO  European Patent Organization 
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HGP  Human Genome Project 
SOU  Swedish government Official Reports (Statens Offentliga Utredningar) 
TRIPS  Trade related aspects of intellectual property rights 
USPTO  United States Patent and Trademark Officer 
WTO  World Trade Organization 
US  United States of America 
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1. Background 
????????????????????????????????????ther shore 
While time is withdrawn, consider the future  
?????????????????????????????????1 
1.1 Introduction 
In 1953 James Watson and Francis Crick published an article in Nature magazine announcing 
the discovery of the DNA double helix.2 In this article the scientists described the DNA 
structure as having interesting biological properties such as self-replication. What these 
British scientists had actually discovered was the source of genetic code. Even though they 
may not have understood the width of their discovery at this stage their announcement was to 
be the starting point for research all over the world and subsequently the development we see 
regarding gene patenting today.  
The template applied to gene patents was the system of absolute patent protection which was 
already in use regarding chemical compounds. The possibility of patenting chemical 
compounds has been available in Sweden since 1978 when Sweden signed the European 
Patent Convention (EPC).3  This means that the judicial aspects applied to gene patents are 
not novel. However, as technology progresses and develops the question of how we limit the 
scope of protection for gene patents is a problem which is increasingly displaying the short 
comings of legal developments in relation to its corresponding technology.  Gene patents are 
granted for a twenty year period which is normal for patents; however, in deviation from the 
norm patents on genes can be awarded for a discovery and not an invention. As long as the 
gene can be synthesized outside of the human, animal or plant body it is legible for 
patentability.  
The possibility of patenting genes has raised a debate fueled by ethical, social, financial and 
legal concerns. As research within the biotechnological field is constantly developing so is the 
debate which surrounds it. Scientists are steadily learning more about the complexities of the 
DNA helix which consequently alters the playing field for the corresponding gene patents.  
                                                 
1 Eliot, T.S Eliot Reading The Waste Line, The Four Quartets and Other Poems, The Dry Salvages. 
2 Watson & Crick, Nature 1953 p. 737.   
3 SOU 2008:20 p. 195. 
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Opinions diverge regarding the scope of protection for gene patents. Some argue that DNA is 
?? ????? ??? ?????? ????????? ????????? ???? ????? ????? ?????? ????? ??? ??????? ??? ?????????? ?????
ownership. On the other hand it is argued that DNA is simply a chemical compound which 
requires patent protection in order to ensure continued research and development within its 
field of application. Subsequently it is argued that patents on genetic material is vital to ensure 
further development due to the high costs affiliated with this field of research which requires a 
right to monopolize ones findings in order to assure continued incentive to invest. There are 
also many who argue that the patent protection has been taken too far resulting in an elevated 
level of protection which does not ensure progress but instead inhibits it. As one studies the 
current debate it becomes inherently clear that this is a highly complex subject that calls for 
balance between economic incentives and socio-political needs.  
The problem which has arisen today is that the scope of rights attached to a gene patent is 
quite uncertain. While reading the legislation it appears as though the rights attached to 
genetic patents are limitless but it is in fact within the courts that the limitations are set. 
However, this is a complex task for the courts who find themselves bound by legislation 
which has been left intentionally open while bearing the burden of the current debate and the 
socio-economic implications of the ethics inherently attached to this area.  
1.2 Purpose  
The purpose of this essay is to examine the legal scope of protection of patents on gene 
sequences. How has recent development in European case law affected the scope of 
protection for genetic patents? The essay aims to summarize the legal development of genetic 
patents as well as predict what the future may hold with regards to the rights conferred by a 
gene patent.  
1.3 Boundaries 
The essay will not cover national legislation within the European Union due to the vast 
amount of time and space that this type of venture would demand. Instead the essay will focus 
on the directive4 and exemplify using Swedish legislation. Since Swedish law regarding gene 
patents is virtually a copy of the directive the Swedish legislation will not be discussed in 
detail.  
                                                 
4 98/44/EC of 6 July 1998 on the legal protection of biotechnical inventions (henceforth called the directive). 
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This essay will also not cover US legislation. Instead selective US case law will be used in 
order to illustrate the arguments voiced within US courts as well as arguments heard in media 
which gives an indication of the attitude towards gene patents.  
The essay does not cover the process of licensing or compulsory licensing of gene patents 
since this is an area which is quite complex and which therefore does not fit within the realms 
of this essay. Even though the licensing system is a part of the patent system it is not 
imperative to study licensing in order to fulfill the aim of this essay.  
1.4 Theory 
In order to fulfill the purpose of this essay I will apply Kaarlo Tuoris theory on critical legal 
positivism. Tuoris theory is based on the notion that there are several layers of the law and 
that these layers interact in a way which has influence on the current state and the future of 
the law. Critical legal positivism does not accept that moral should be something separate 
from the law, but instead, that law and morals are interconnected.5 Applied to this essay 
Tuoris theory allows for an analysis based on the notion that different structures interact with 
the law thus allowing judicial, financial and moral aspects to be included in the analysis.  
Tuori has also coined the concept of the two faces of the law where one face consists of the 
law as a legal order i.e. norms. The second face of the law is that the law can be approached 
as a set of social practices which reflect how the law is practiced. The two faces consist of 
different ways of viewing the law but which are constantly interacting as one cannot exist 
without the other.6  
Critical legal positivism describes three levels of the law; the surface structure, legal culture 
and the deep structure. The laws surface level is most subjected to changes and consists of 
statues and regulations, case law and documentation from legal sciences.7 The legal culture 
changes more slowly and consists of how active lawyers practice the law8 for example: what 
is argued and how is this presented.9 The legal culture is also consists of legal principles 
which guide interpretations of the law.10 The deep structure changes very slowly and is based 
around the notion that there is a common core throughout different legal systems.11 This 
                                                 
5 Tuori, Critical Legal Positivism p. 29. 
6 Ibid, p. 121. 
7 Ibid, p. 154. 
8 Ibid, p. 165. 
9 Ibid, p. 167. 
10 Ibid, p. 192. 
11 Ibid, p. 183. 
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structure is formed by fundamental human rights and broad normative notions.12 The deep 
structure is not directly apparent but rather exists on a hidden level where lawyers are not 
???????????????????????????????????????????????????13  
Tuori stresses that all three levels of the law are interconnected in that the surface level of the 
law sediments down towards the deeper levels.14 This entails that what is found in the legal 
culture and deep structure has once been on the surface level and has slowly moved down 
within the layers. 
???????????????????????????????ritical legal positivism by aiming to present the different layers 
of what has effected gene patents developments and its potential future.  
1.5 Method 
This essay is composed of a compilation of different aspects which have affected and are 
affecting gene patents. In order to fulfill the aim of the essay it is necessary to sway from the 
traditional legal method, in order to include all of the necessary angles, which entails that this 
essay will instead present a socio-political view on gene patents in combination with 
legislative motives.  
Since the biotechnical industry is largely motivated by revenue there is a need to include 
certain financial aspects in order to present the full aim of the system of gene patents. This 
will be done by compiling different opinions voiced in media and by formal declarations 
made by representatives of the biotech industry. 
In contrast to the financial aspects it is necessary to present certain human rights and ethical 
aspects which are fulfilled by studying the past and current debate on access to affordable 
medicines and ethics on patenting genes. Since gene patents presents an opportunity to 
discuss sociopolitical values this will also be touched upon.  
Gene patents have evolved out of the administrative arena which has largely ruled out the 
influence of the traditional legislative process. In order to obtain a clear reflection on the 
development of gene patents case law from the European Patent Organization (EPO), 
European Court of Justice (ECJ) and US courts will be discussed. These cases will also be 
compared to each other in order to determine the current scope of protection and the potential 
future of gene patents.  
                                                 
12 Ibid, p. 192. 
13 Ibid, p. 185. 
14 Ibid, p. 201. 
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1.6 Outline 
The essay will firstly present a basic background regarding DNA and related concepts. This 
section of the essay is necessary in order to provide the reader with some fundamental basics 
which will allow the rest of the essay to be more easily comprehended.  
After this the essay focuses on current legislation and related case law. Specifically the essay 
will discuss the directive on the protection of biotechnical inventions, the European Patent 
Convention and TRIPS.  
The subsequent section then describes the debate which surrounds gene patents. This section 
will identify the scope of opinions on what should be the rights of the patent holders and in 
what situations patents for genes should be granted.  
Then the Monsanto-??????????????????????????????????????????????????????????????????????????
rulings are presented.  
The subsequent sections will focus on exploring the effects of the Monsanto-case as well as 
predictions for future developments of gene patents. Since Europe is not impermeable to the 
judicial developments in the US relevant US case law and related developments will also be 
discussed. The aim of presenting US case law is to provide the reader with a more diversified 
prediction of the future of gene patents.  
2. DNA 
In order to help the reader understand the distinction between some basic concepts which are 
often used while discussing genetics and the background to gene patens this section aims to 
provide definitions and basic explanations. 
2.1 The basics: chromosomes, DNA, genes and genome 
All plant and animal cells contain chromosomes in varying numbers; for instance human cells 
contain 4615 chromosomes organized into 23 chromosome pairs.16 Chromosomes are built up 
of protein and several DNA double helixes.17  
DNA is can be described as the code for all living organisms and most viruses. DNA takes the 
shape of a double helix which is basically two strands wound around each other. The strands 
                                                 
15 Some individuals can have more or less than 46 chromosomes, for instance people with Down syndrome have 
47 chromosomes. 
16 Calladine et alia, Understanding DNA, p. 4. 
17 Calladine et alia, Understanding DNA, p. 5. 
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are linear polymers made up of amino acids.18 The amino acids are called A (adenine), G 
(guanine), T (thymine) and C (cytosine). These amino acids are arranged in pairs within the 
DNA double helix19 and are subsequently the building blocks of the double helix.20  
A gene is a distinct part of a DNA double helix which carries the code for a distinctive trait. 
Genes have a very important task in the body; they produce different proteins. These proteins 
are what make up the body and its functionality. For instance enzymes which catalyze 
digestion of food is a protein produced by a certain gene which sits within a DNA strand.21 
The human body contains about 30 000 genes.22 
The genome is a complete set of hereditary information within a full set of chromosomes.23 In 
other words; a genome consists of all genes within an individual human, plant or other living 
organism.   
2.2 The Human Genome Project 
The human genome project (HGP) which is also known as the Hugo project was an 
international venture aiming at mapping the entire human genome. The HGP was a 
collaboration between the US Department of energy, the UKs Wellcome trust, Japan, China, 
France Germany etc.24  One of the aims of the project was to allow biotechnical access to the 
human genome in order to further biological research on human DNA. The project started in 
1990 and was completed by 2003.25 The project was successful in mapping the human 
genome and the judicial repercussions of the HGP results will be discussed further in chapter 
9. 
2.3 Genetics in history 
Crude attempts at genetic manipulation have been applied for decades. This is a dark area of 
history where the notion of applying selective sterilization to manipulate the coming 
population spread through several parts of the world.  
                                                 
18 King & Stansfield, A Dictionary of genetics, p. 268. 
19 View appendix 1 for an illustration. 
20 Klug & Cummings, Essentials of Genetics, p. 6. 
21 Calladine et alia, Understanding DNA p. 11. 
22 Primrose & Twyman, Genomics: application in human biology p. 19. 
23 King & Stansfield, A Dictionary of genetics, p. 140. 
24 www.ornl.gov/sci/techresources/Human_Genome/home.shtml accessed on 2011-11-22. 
25 Ibid. 
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In the US in 1907 Indiana passed a law requiring sterilization for genetically inferior 
individuals, amongst these were ?????????????????????? ???????? ??????????????????????.26 This 
law was the result of the lobbying of the eugenics movement. Eugenics was first named by 
Francis Galton in 1883 and refers to the belief that human characteristics are inherited from 
parents to the child and thus the eugenics movement believed that the human race could be 
made stronger and more intelligent by the use of selective breeding. By 1940 a total of 30 
states in the US had ratified similar laws which resulted in more than 60 000 involuntary 
?????????????????????????????????????????????????????????27 
The Nazi government in Germany had a similar notion, which is probably not a surprise to the 
reader. However, the Nazis argued the need for selective sterilization mainly from an 
economical point of view. In Nazi propagated that the high cost of caring for patients with 
incurable diseases was the result of poor breeding and which consequently was unwanted.  In 
1933 the law on preventing hereditarily diseased progeny was passed which enforced 
involuntary sterilization on bearers of hereditary diseases for example hereditary blindness or 
deafness as well as alcoholics and individuals living in poverty.28 
In 1934 and 1941 the Swedish government voted and passed a law which allowed involuntary 
sterilization on the basis of hereditary, medical or social indications.29 In 1975 the possibility 
of forced sterilization was removed but by then 63 000 individuals had been sterilized 
whereof 50 % involuntarily.30 Out of the total 63 000 individuals sterilized 93 % were 
women.31 
What the wide spread eugenics movement clarifies is that people have been fascinated with 
the ability of manipulating the human genome for over a century. In short this means that the 
antecedent of gene patents has a dark history which illustrates how far humans were willing to 
go in the venture of producing a stronger race.  
2.4 Gene patents: areas of application 
Major advances within the areas of medicine and agriculture have been made possible by the 
use of biotechnical inventions. In an effort to supply the reader with an idea of the areas of 
                                                 
26 www.iupui.edu/~eugenics/ accessed on 2011-09-26. 
27 Allen, Technology Review 1996, p. 23-31. 
28 Ibid. 
29 SOU 2000:20 p. 15. 
30 Ibid, p. 16. 
31 Ibid, p. 16-17. 
 15 
application for biotechnical inventions this section of the essay will introduce the most 
common uses.  
2.4.1 Agriculture 
By using hybridization to perform genetic manipulations plants have been improved in four 
main ways: 
1. Increased yields. 
2. More resistant to pests and diseases. 
3. Combination of traits from different species. 
4. Increased levels of a certain desirable quality.32 
By genetic research scientists have reached great results regarding several different kinds of 
plant. For instance in the US it is estimated that genetic enhancement has increased the crop 
yield by a threefold. As is mentioned above it is also possible to produce crops with specific 
desirable qualities which has been done in, for instance, Mexico where scientists have been 
able to produce a type of corn with elevated levels of protein.33 The result of the research can 
be limitless, imagine, for instance, a plant which can grow on minimal water while yielding 
crops with maximum levels of nutrients. This type of invention could be life saving in 
countries struck by famine and drought.  
By selective breeding scientists have also produced chickens which grow faster and lay more 
eggs as well as cows and pigs that grow faster and bigger.34 One example which has appeared 
frequently in media is the cow breed called Belgian Blue. While developing the breed Belgian 
Blue, which displays double the muscle mass of normal cows, an intricate method of gene 
mapping and selective breeding was used.35  
2.4.2 Medicine 
Presumably medical development is the most common association to biotechnical inventions. 
While probably being the most controversial area of research it is also an area which many 
people depend upon.  
To name one; the production of human growth hormones was a result of a genetic patent 
which was held by an American company and a method for reproduction produced by the 
Swedish pharmaceutical company called Kabi-Vitrum. Kabi-Vitrum purchased the rights to 
                                                 
32 Klug & Cummings, Essentials of Genetics, p. 11. 
33 Ibid. 
34 Ibid. 
35 Grobet et alia, Nature Genetics 1997, p. 71-74. 
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the gene patent for growth hormones from the Americans and inserted the gene into E-coli36 
bacteria.37 The bacteria then started to produce large quantities of the hormone and the protein 
could be purified from the bacteria. This bacterium becomes a gene manipulated organism 
once the gene is inserted into it. This process is applied to produce medicines for several 
different diseases for instance diabetes, hemophilia, proteins which dissolve thromboses.   
Another area of great promise is that of gene therapy. Today it is possible to insert modified 
genes into human cells in order to replace a damaged gene which is causing a defect.38 The 
long term aim of gene therapy is to permanently treat diseases where currently existing 
medicines can alleviate symptoms but not cure the patient.  For instance the method could be 
used to replace genes which make the carrier more prone to cancer with healthy genes. Gene 
therapy is in its early stages and is still being tested but may develop into a theoretically 
limitless tool to treat genetic diseases.39 There are two types of gene therapy; somatic and 
zygotic. There is an important distinction to be made regarding gene therapy where somatic 
gene therapy results in the replacing of a gene in that specific individual which entails that 
this individual cannot pass the gene on to its offspring.40 Human zygotic therapy is a method 
where certain genes are replaced by other genes in such a manner that they will be inherited 
??? ???? ?????????? ??????????41 ????? ?????? ????? ????????? ????? ????????????? ????????? ?????? ???
????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????ed by a healthy gene. Zygotic gene therapy has, for 
many years, been successfully used by scientists in tests on animals.42 
These are only a few examples of the areas of biotechnology which have resulted in progress 
in medical research. Since the areas of a???????????????????????????? ??????????? ??????????? ?????
safe to say that it generates a very large amount of money and is of great importance for the 
sustenance of many people.  
3. EPO & EPC 
Before the directive was implemented in 1998 European gene patents have been distributed 
via the EPO. The development of admissibility of gene patents within Europe was instigated 
                                                 
36 A bacteria naturally found in the intestines of humans and animals. 
37 Brändén, Genteknik, kloning och stamceller, p. 20-21. 
38 Primrose & Twyman, Genomics: Applications in Human biology p. 178 f. 
39 Ibid, p. 14-15. 
40 www.brown.edu/Courses/BI0032/gentherp/IIAB.htm accessed on 2011-12-17. 
41 www.genteknik.nu/index.asp?id=389&typ=print accessed on 2011-11-29. 
42 Brändén, Genteknik, kloning och stamceller p. 79. 
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by the application of the Harvard Oncomouse patent as early as 1984.43 In order to understand 
the relationship between the legislation constructed by the European Union and the European 
Patent Office this section aims to clarify and decipher the importance of the EPO and its 
relation to the legislation within the European Union.  
3.1 What are the EPO and the EPC? 
The EPO is an intergovernmental organization which was constructed in 1977.44 The EPC 
was signed in Munich in 1973 and is the legal foundation of the EPO. The EPO currently 
holds 38 members, whereof Sweden joined in 1978.45   
The EPO grant patents which are upheld throughout their 38 member states. In 2010 the EPO 
granted 136 700 patents whereof 2194 were in biotechnology.46 
3.2 The relationship between the EPC and the directive 
In order to avoid clashed between the EPC and the directive certain provisions were met to 
secure that the compatibility of the two documents. Within the Implementation regulations47 
of the EPC rule 26 clarifies that the EPC should be interpreted within the light of the 
directive. The directive also refers to the EPC in recital 15 where it is stated that the EPCs 
provisions should be regarded while implementing the directive. It is therefore clear that there 
the two documents are interconnected which indicates that there is a desire to unify the two 
systems to avoid incompatibility. 
3.3 Opposing a granted European patent. 
If the decision of the EPO to grant a patent is believed to be incorrect a third party may 
request that the EPO re-examine the application.48  The third party must file an opposition 
with the EPO within nine months of the grant of the patent.49 The opposition must be on the 
grounds that50: 
- The patented subject is not patentable under article 52 to 57 i.e. the subject is not new, 
inventive or is not industrially applicable. 
                                                 
43 Patent number EP0169672 & www.epo.org/news-issues/issues/biotechnology.html accessed on 2011-12-01. 
44 www.epo.org/about-us/organisation.html accessed on 2011-09-29. 
45 SOU 2006:70 p. 106. 
46 www.epo.org/about-us/statistics/granted-patents.html  accessed on 2011-09-29. 
47 The full name is: Implementing regulations to the on the grant of European patents as last amended by the 
decision of the Administrative Council of the European Patent Organization of 26 October 2010. 
48 EPC article 99. 
49 Ibid. 
50 EPC article 100. 
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- The invention is not disclosed in enough detail. 
- The patented matter extends beyond the content of the application. 
The review of the patent application is an administrative process which is performed by 
opposition divisions of the EPO.  
The objection is firstly administered by an Opposition Division consisting of three technically 
qualified examiners whereof at least two should not have been involved in the grant process.51  
If the decision of the opposition division is unsatisfactory to any party they may file an appeal 
which will then be administered by the technical boards of appeal52 within two months53 of 
the decision of the opposition division. There are currently 27 Technical Boards of Appeal in 
addition to the Large Board of Appeal, the Enlarged board of appeal, and the Disciplinary 
Board of Appeal.54  
4. Directive on legal patentability of biotechnical inventions 
4.1 Background and legislative motive 
The directive was preceded by the American case Diamond v Chakrabarty55 from 1980 where 
it was concluded that a live microbiological organism was patentable under US law. In an 
effort to harmonize European law and counter-act biotechnical companies fleeing Europe to 
relocate in countries with more generous patent legislation56, the EU followed Americas lead 
and approved the directive in 1998.   
The road towards the directive was not, however, straight. After seven years of revised drafts 
of a biotechnology directive the European Commission tried to convince the parliament to 
adopt a version of the directive in 1994. The ethical discussions rose high as some argued that 
the moral debate had been taken into account adequately while outlining the directive whilst 
others, mainly the Green Party, disagreed.  For instance, Linda Bullard who was a staff 
member of the Green Party stated that ???? ????? ????? ???????????? ??????? ?????? ???????????
against patents on parts of the human body - including genes- under any circumstances, is 
morally obliged to reject this compromise?.57 The 1994 version of the directive was never 
                                                 
51 EPC article 19(2). 
52 EPC article 107. 
53 EPC article 108. 
54 www.epo.org/about-us/boards-of-appeal.html accessed on 2011-12-06. 
55  Case number 447 U.S. 303. 
56 Scalise & Nugent, Fordham International Law Journal, 1992, p. 991f. 
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enforced due to lack of support in the European Parliament. On the rejection of the directive 
Peter Doyle who was the executive director Zeneca Ltd58 stated ???????????????????????????????
????????????????????????????????????????????????????????????????????????????????????????59 It 
became clear that there was a large gap between the will of some of the members of European 
Parliament and the biotech industry. The setback for European gene patents was not to be 
long lived; in 1998 the directive was reconsidered in the Parliament and this time it was 
approved.  
The difference between the legislative development in the US and Europe is that ethical 
aspects had to be included in the discussion on the directive. The basis for the ethical 
discussed was that the European Patent Convention states that inventions which are contrary 
to ??????? ??????? ??? ?????????60cannot be patented. The effect of this prohibition was that 
ethics were a natural brake in the distinction of the directive where it was not a legislative 
based factor in the development of US policy.61 Since the directive and the EPC are 
interconnected this resulted in a more long lived ethical debate with a heightened legitimacy.  
After several years of debates throughout the member states the directive was finally accepted 
in 1998.62 Even though the debate had been fueled by widely diversifying opinions it was 
made clear that the aim of the directive was to unify the different legislations within Europe in 
order to avoid barriers to trade.63 It had also been noted that the developments within genetic 
patents were basically demanding protection for their discoveries in order to allow these 
industries to grow.64 Research and development of new products related to genetic sequences 
was notably very expensive and in order to further stimulate these businesses one of the aims 
was to give them further encouragement by allowing genetic patents.65  
4.2 Claim against the directive  
Besides the discussion concerning ethics on allowing patents on genes, mentioned above, 
there was turbulence within the European Union while voting on the future of the directive. 
Sweden, along with another eleven member states voted to implement the directive while the 
                                                 
58 A British biotechnical company which fused with the Swedish biotechnical company Astra in 1999 to create 
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59 Dickson II, Nature1995, p. 103. 
60 EPC article 53. 
61 Kevles & Berkowitz, Brooklyn Law Review 2001 p. 243. 
62 Scalise & Nugent, Fordham International Law Journal 1992, p. 992. 
63 Directive 98/44/EC preamble article 5. 
64 Ibid, article 1. 
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Netherlands voted against the directive and Italy and Belgium chose not to vote.66 After the 
directive was passed the Netherlands filed a claim against the European Parliament67 which 
was supported by Italy and Norway. 
The claim presented six separate pleas by the Netherlands; amongst them were breaches 
against the principle of subsidiarity, breach of the principle of legal certainty, breach of the 
respect for fundamental respect for human dignity, breach of obligations under international 
law etc. However, all pleas were declined in court leading to the courts favoring the side of 
the European Parliament and the subsequent adaptation of the directive. The courts clearly 
expressed that they favor the side of the parliament and that the directive is clear enough not 
to interfere with human dignity.68 
Even though the Netherlands claims were not favored by the courts this case clearly illustrates 
how questioned the directive and patents on genes were before the implementation of the 
directive. The case and the attitudes towards patenting genes will certainly have effect in the 
development of gene patents since the directive is very vague and does not specific limitations 
which will then leave individual courts to decide the scope of this form of patents. The essay 
will discuss this topic further under chapter 9. 
4.3 Invention vs. Discovery 
As a principal rule an object viable for patentability has to be an invention and could not 
constitute a mere discovery. This was the historical point of view but as the directive was 
implemented it became clear that those rules would have to be adjusted with regards to gene 
patents. Patentable gene sequences can occur naturally which means that the patentable 
subject is not an invention in the common use of the word but merely a successful 
development in science where a gene strand has been extracted in order to be utilized for a 
purpose.  
Instead of claiming that discoveries should be allowed to be patented the directive states that a 
genetic strand which can be synthesized outside of its natural habitat (for example a human, 
plant or animal body) should be considered an invention.69 By this method the parliament 
???????????????????????????????????????????????????????????????????????????????????????????????
to re-define the concept of invention within biotechnology. Simply put the commonly used 
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definition of an invention does not equal the legal definition.70 By using this method the 
directive does not open up the flood gates for masses of new patent applications regarding 
discoveries it merely shifts the concept of an invention to fit the purpose. The directive simply 
put expands the concept of an invention in order to include gene sequences.  
4.3.1 The Relaxin-case 
The reader might find it useful to know that this concept of expanding the word invention was 
not novel to European patents when the directive was adopted in 1998. The EPO had granted 
a patent on the human gene which codes for the protein Relaxin in 1995.71 This entails that 
patents had already been awarded discovered and synthesized gene strands prior to the 
implementation of the directive.  
It is important to note that within the EPC a similar legislative standpoint is enforced 
regarding discoveries where article 52.2.a excludes discoveries from patentability. This 
verdict can be considered to have laid the ground work for a more extensive interpretation of 
the word invention and a more lenient attitude towards gene patents. 
4.4 Criteria for patentability 
The directive fixes a set of rules for when gene sequences can be eligible for patenting. 
Within this directive the parliament has chosen to continue using the previously ascertained 
criteria for patentability. These elements will be discussed here in order to provide the reader 
with the frame work for the distinction of when a gene can be patented or not.  
4.4.1 Industrial Applicability 
The aim of the industrial applicability criteria is to limit patent applications to those which 
actually have a discovered use. Regarding gene sequences the directive clearly states that a 
patent cannot be granted if the patentee does not know the function of the patent.72 This 
means that it is not enough to simply identify a gene in order to be granted a patent; the 
applicant needs to be aware of what the gene codes for and subsequently how this gene could 
be utilized. 
The directive does not clearly define the element industrial application; however the EPC 
does provide a definition and since the directive states that the two documents are 
                                                 
70 Pamp, Intellectual property in Science, p 215. 
71 EPO case number T 0272/95. 
72 98/44/EC of 6 July 1998 on the legal protection of biotechnical inventions recital 23. 
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interlinked73 the definition from the EPC is presumably applicable on the directive. The 
demand for susceptibility for industrial application74 invokes that the patentable subject can 
be used in any industry, including agriculture.75 In the case of gene patents these are mainly 
???????? ???? ????????????? ???????????? ????? ?????????? ??? ????? ????? ?????? ??? ??? ????? ???? ????
applicant to prove the actual use of the gene sequence, it is sufficient to express a possible 
use.76 However, it is clearly stated within the directive that the industrial application must be 
stated on the patent application.77  
The directive chooses to limit the possibility of patenting gene sequences to the cases when 
the applicant can show an industrial application but at the same time the definition of the 
element industrial application is very wide. By extension it seems that the European 
parliament has chosen to leave the definitions of industrial applicability to the courts since 
there are no explicit limitations provided within the directive. In spite of the seemingly 
diaphanous requirement of industrial application for a gene the two subsequent sections will 
elaborate on the limitations of the criteria. 
4.4.1.1 BDP Phosphatase - case 
In the case BDP Phosphatase/MAX PLANCK78the Max Planck institute had applied for a 
patent for BDP1-polypepti which was thought to be able to neutralize another protein in the 
body which was believed to increase the risk of developing colon cancer. In the patent 
application the Max Planck institute had submitted that BDP1 could be used in 
pharmaceuticals. The EPO decided that the patent could not be upheld since the applicant had 
not presented how the patent was to be used specifically. The EPO stressed that there had to 
be a difference between what could be patented and what was merely the result of interesting 
research.79 The EPO further expresses that it is not valid to patent genes as a method of 
monopolizing potentially interesting research areas.80 
The case clarifies that a further level of detail regarding the genes industrial applicability is 
needed in order for a patent to be issued.  
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4.4.1.2 Bioinformatics & the ICOS case 
Bioinformatics is the interdisciplinary study of biology and information technology81. By 
using databases containing information on known DNA sequences and their functions it is 
possible to calculate the probable function of an isolated strand of DNA. This tool is 
immensely useful to researchers as it gives them a reasonably accurate prediction of the 
function of a gene. However, it is important to note that the database can only supply a 
predicted function; the prediction is not a guarantee of the correct function.82 Because patent 
applications are often submitted early in the research process this has meant that the predicted 
function has repeatedly been used in applications. The issue of patent application with a 
speculative industrial application was addressed by the EPO in the ICOS-case. 
ICOS was one of the largest biotechnical companies in the US until 2007 when it was sold to 
Eli Lilly.83 ICOS had applied for and been granted a European patent84 for a DNA sequence 
which they claimed could be used as a receptor. Two separate biotechnical companies filed an 
appeal which was administered by the opposition division who passed judgment in 2001.85 
The case examines the definition of industrial applicability and when a DNA sequence is to be 
regarded as reaching the standards set by the EPC. ICOS argued that EPC article 57, which 
states the need for an industrial application of a patentable subject, is fulfilled if the product 
can be used in any industry.86 As mentioned earlier ICOS argued that the DNA sequence 
could be used as a receptor within the area of immunology which they had stated on their 
patent application. However, the opposition division found this argument lacking stating that:  
?In view of the requirement of industrial application as set in Article 57 EPC in conjunction 
with Rule 23b-23e EPC87, the invention cannot be acknowledged as industrially applicable 
because industrial applications are not disclosed in the patent application?88  
This citation stresses that article 57 of the EPC, which merely states that industrial application 
is fulfilled if the invention can be used in industry, should be interpreted alongside with 
current rule 26-29 which state that the directive can be used as a basis for interpretation. The 
courts state that the mere indication of a use cannot be acknowledged as fulfilling the 
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industrial application criteria. The Opposition Division further stated: ?????? ???? ??????????
uses disclosed in the application are speculative, i.e. not specific, substantial and credible as 
????????????????????????????????????????????????.89 The Opposition Division hereby states that 
the patent application requires further specification than what ICOS had submitted to fulfill 
the industrial application criteria. Within the ICOS patent application was a disclosure of an 
area of use for the gene; however, the application was not considered specific enough which 
lead to the Opposition Division revoking the patent. This case can be seen as a turning point 
for the EPO where they now apply elevated standards regarding industrial applicability and 
thus require further detailed use from the patentee. Even though the demand for an industrial 
application within article 57 is very loosely stated this case displays a heightened 
interpretation of the wording of article 57 consequently raising the bar for the criteria of 
industrial application.  
Since this case was not appealed the precedent can be discussed, however the demand for a 
more specific level of industrial application has been upheld since the judgment was passed in 
2001. This will be discussed further in chapter 9. 
4.4.2 Novelty 
The novelty requirement in article 3.1 of the directive means that a gene cannot be patented if 
it is previously known to the public. The public does not have to entail a large collection of 
people, it is enough for the gene to be known somewhere in the world to a certain group of 
people for the patent application to fall short of acceptance. The patented subject does not 
have to be in industrial use, it is enough that it is known by word of mouth or by any 
documentation.90  
One of the complexities which arise while discussing genet patents is that it could be argued 
???????????????????????????????????????????????????????????????????????????????????????????????
other organisms. However, it has been stated that the previous existence of a gene does not 
make it public knowledge. In the previously mentioned EPO case Relaxin the courts announce 
that since the gene is not mentioned in any previous documentation it is acknowledged as 
being new.91 ??? ?????? ?????? ???? ???????? ??????????????? ?????? ????? ?? ????? ???? ?o be 
documented previously in order for it to fall short of the novelty criterion, it is not enough that 
it merely exists.  
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4.4.2.1 Translational inhibition-case 
This case tests the boundaries of when an invention can be considered known to the public 
and fall short of the novelty criteria.  
In the case Translational inhibition/RESEARCH FOUNDATION92 a patent application was 
filed with the EPO for a gene which consisted of three vital parts. Other biotechnical 
companies argued that this gene had been presented to the public both via an article and at a 
seminar which was attended by 100 people. However, in the article only one part of the gene 
was presented and the EPO found that the presentation could only be considered public if the 
patentable material was presented clear and unmistakable.93 Because the article was missing 
vital information the novelty criteria was considered to be upheld.  
The gene was also presented at a seminar which was attended by 100 people.  The EPO held 
that because the attendants were obliged to sign non-disclosure agreements the presentation of 
the invention could not be considered public knowledge.94  
4.4.3 Inventive step 
The final criterion enforced under the directive is that the patent application must contain an 
inventive step. This term, along with the other elements of patentability, is not defined by the 
directive. However, parallels can be drawn to the definition which is supplied in article 56 of 
the EPC. Herein an inventive step is defined negatively as something which is not obvious to 
someone who is skilled in the particular art. Someone skilled in the art is a person who has 
access to the latest literature on the subject and who has the ability to perform experiments.95  
By requiring an inventive step to administer a gene patent the legislator aims to secure that 
patents should solely be awarded to those inventions which can be considered an inventive 
feat.96 In an attempt to crystallize the content of the element inventive step the EPO has 
defined it as ????????????????????????????????????????????????????97 The aim appears to be to 
reject patent applications which risk blocking the development of research.  
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In practice this criteria seems to be quite difficult to anticipate for applicants which has 
resulted in that over half of the appeals made to the EPO are in regards to a lacking inventive 
step.98 
4.5 Absolute product protection  
Absolute product protection is basically a patent where the patent rights are not bound by the 
specifications on the patent application.99  
Before gene patents were admissible absolute product protection was awarded patents on 
chemical compounds. This extensive type of protection came firstly from the US where it was 
enforced after world war two. In Europe this principle was legislated in 1950 and it was 
implemented in Sweden in 1978.100 The principle is not crystallized directly within the EPC 
or the directive but can be seen through studying case law and indirect effects of article 6 of 
the directive. 
4.5.1 Absolute product protection on gene patents 
Article 6 of the directive establishes that the applicant needs to state the industrial application 
of the gene they wish to patent. This article has been translated into the Swedish patent act 8 
§. It is misleading to assume that the demand for industrial application regarding gene patents 
limits the patent to that particular the application. In fact, this is not the case; the demand for 
industrial application is a mean of hindering applications from coming in before the function 
of the gene has been determined.101 The nature of absolute product patent is that once the 
patentee has gained a patent for a gene the rights conferred by the patent are not limited by the 
industrial application of the patent application but extends to all areas of use for that gene. In 
other words the reason that the gene patent demands an industrial application is only to ensure 
?????????????????????????????????????????????????????????????????????????????????????????????????
use since this risks creating a dead-lock in research development. In the previously mentioned 
case BDPA Phosphatase/MAX PLANCK ?????????????????????????????? ???? ????????? ????????
industrial application, states: ????? ???????? ??? ????????? ?? ??????? ??? ???? ??? ???????? ???
??????????????????????????????????????????????.102 It is also important to note that a gene can 
code for several different proteins which means that the industrial application stated on a 
patent application can be one of many functions which that gene codes for.  
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The question which arises is if absolute product patent for a gene then entails that that the 
patent holder can monopolize that particular gene? This is not the case. If one actor has been 
awarded a patent for a gene and another actor wishes to patent that particular gene but for 
another industrial application this is possible.103 The situation would then be that the owner of 
the first patent is the primary patent holder while the second actor would have to get a license 
from the first actor holding the primary gene patent in order to be able to utilize the gene in a 
product.104 If the holder of the patent does not wish to comply and award a license it is 
possible to have a compulsory license expedited105, but this is not explored further within the 
scope of this essay.  
Assigning absolute product protection has been widely discussed. Some find it absolutely 
natural to award absolute product protection to genes arguing that the process is so similar to 
that of discovering chemical compounds that it is only natural to award an elevated level of 
protection to genes as well.106 This is a similar point of view as the EPO took in the above 
mentioned Relaxin-case where genes were concluded to be chemical entities. The debate of if 
the absolute product protection should be implemented throughout Europe has been very 
diverse and long. Within the Swedish Official Reports107 the Swedish government carefully 
followed up the implementation of absolute product protection and stated the advantages and 
disadvantages of such a vast protection: 
Advantages: 
1. A patent limited to the industrial applicability is difficult to define which might lead to an 
increase in patent infringement processes. 
2. Research corporations may chose not to perform research as they find the level of 
protection too limited. 
3. The problem of royalty stacking108 may increase resulting in a decreased incentive to invest 
in research. 
4. Absolute product protection results in a higher incentive to invest in research. 
Disadvantages: 
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1. Absolute product protection means allowing a greater level of protection then the 
????????????????????? ????????????109 
In total the committee of the Swedish preparatory works examined the effects of absolute 
product protection found that the advantages played a larger practical role and thus this form 
of patent protection for genes is still applied.  From examining the stated advantages it 
becomes clear that the committee has largely focused on practical administrative factors of 
absolute product protection and has thus reduced the importance of obtaining a balanced 
patent system.  
Notably not all members of the EU apply absolute product protection within their national 
legislation. Germany, France, Italy, Luxembourg and Switzerland have chosen to assign a 
more restrictive scope of protection on gene patents.110 One of the aims of the directive was to 
unify the EUs member states legislation with regards to gene patents and the varying 
applications of absolute product protection means that this goal has not been met fully.  
5. TRIPS 
Sweden has been a member of the European Union since 1995 and with this membership 
followed an obligation to also become a member of the World Trade Organization111 (WTO). 
Beside the separate member states of the EU requiring membership in the WTO the EU is 
also a member112 thus is important to note the influence that WTO law can have on the 
legislation of the EU and its member states. 
5.1 What is TRIPS 
Trade related aspects on intellectual property rights (TRIPS) is a legal WTO document. The 
document consists of a legal framework recognizing intellectual property rights which are to 
????????????????? ???????????????????? 
5.2 The politics behind TRIPS 
Even though the original GATT113 document signed in 1947114 established some basic 
positive rights for IP it would take until the Uruguay Round which spanned from 1986-
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1994115 to construct TRIPS. Separating and expanding the IP rights was largely a result of 
political discussions. It was argued that free trade would be largely hindered by some member 
states lacking IP rights rendering the removal of barriers to trade basically meaningless.116 
The reason for this argument was the fear that a product could be successfully exported into a 
nation where the trademark and product could be legally copied and distributed leaving the 
incentive to trade between the parties greatly diminished.117  
The marriage of trade and intellectual property rights through TRIPS has been greatly 
criticized by those who find that this systematically excludes developing countries from 
developing while allowing developed countries to remain thriving.118 One argument put forth 
??? ???????????????????????????????? ??? ????? ???????????????????????????????????????????????
?????????????? ?????? ???????? ???????? ?????????? ?????????? ??? ????????119 The enforcement of 
TRIPS was largely a result of the US and other industrialized countries lobbying in the WTO. 
Herein the industrialized countries argued that the developing countries were constricting the 
trade opportunities for industrialized countries by production and sale of counterfeiting 
products.120 The basic notion seems to be that the developed world forced the less developed 
member states to agree to TRIPS which resulted in a situation where the developing world 
control intellectual property rights and thus hinder developing countries from expanding.121  
5.3 Relationship between TRIPS and European Law 
Membership in WTO binds its members to uphold the TRIPS document. Notably in Merck 
Genéricos v Merck and Co the ECJ expressed that it was up to the individual member states to 
chose if they wished to give the TRIPS agreement direct effect or not.122 The TRIPS 
agre????????????????????????????????????????????????????????????????????????????????????????
law shows a clear striving to act in accordance with the TRIPS agreement.  
In Dior and Others the courts proceeded to clarify that the when community legislation is 
applicable these provisions should be interpreted with TRIPS in mind.123 ????? ?????????? ???
note that even though TRIPS does not have direct effect the agreement needs to be kept in 
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mind while discussing European law since it, according to above mentioned case law, can 
influence the interpretation of provisions of European intellectual property law. 
6. Opinions on gene patents 
Since patenting genes is a highly controversial subject it has fired an ethical debate which has 
been in progress for decades. The debate descants the question of legibility of gene patents as 
a concept as well as the different views on appropriate limits on the scope of rights attached to 
genetic patents. 
 In a decision from 1998 the EPOs board of appeal states:  
???????????????????????????per balance must be found between, on the one hand, the actual 
technical contribution to the state of the art by the invention disclosed in said patent or patent 
application, if any, and, on the other hand, the manner of claiming so that, if patent 
protection is granted, its scope is fair and adequate??124 
 Patenting genes is a very complex issue which does not appear to encompass correct answers 
merely adequate compromises in an effort to reach a balanced system. This chapter aims to 
present varying views on the span of rights connected to gene patents in order to allow the 
reader to gain an understanding of the debate.  
6.1 Arguments supporting gene patents 
It is apparent that there are many strong forces who have acted towards gaining the right to 
patent genetic materials. If the contrary was instead a fact then we probably would not be able 
to patent genetic materials the way which is possible today. It has already been mentioned that 
the ability to patent genes originated in the US in 1980 and that this development lead to a 
debate in Europe which aimed to allow European patents within the same arena. One of the 
aims of expanding the realm of patents to include genetic material was to allow European 
companies to compete on the same level as corporations based in the US. This section of the 
essay will present the arguments for allowing gene patents.  
6.1.1 Encourages research 
One of the most founded arguments which re-occur in gene patent discussions concerns 
financial considerations. Since gene patents are granted within the US it is almost impossible 
to disallow the same level of protection within Europe. Hampus Rystedt, who was a manager 
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at the Swedish patent and registration office, argued that if we had not enforced gene patents 
then this would inevitably entail that research would not be performed by private research 
foundations and this would mean that all research would instead be dependent upon 
government funding.125 The reason for his argument is quite simple, private research 
foundations would lack financial incentive to develop medicines and perform research. 
Genetic research is very costly and private corporations would require security in the form of 
a patent protection in order to motivate them to invest in this type of research.  
It should also be noted that the line of argument which aims to keep researchers motivated has 
also been presented in Australia where a change in the law which threatens to rule out gene 
patents have lead to learned individuals expressing their fears that this could lead to research 
companies fleeing the country and thus stiffening scientific developments within genetics.126 
As a comparison it should be noted that in the US a drug is estimated to have cost $800 
million and have taken 12-15 years before reaching the market.127 Even though not all gene 
patents are used to produce pharmaceuticals this comparison might give the reader an idea of 
the vast amount of money which is consumed during medical research and the need for patent 
protection as an incentive to invest such vast amounts of money.  
6.1.2 A gene patent is not owning life 
Harvard Professor and CEO of the company Human Genome Science, William A. Haseltine,  
introduces a scientific and ethical argument for gene patents where he wishes to clarify what 
lies behind a gene. Haseltine argues that a common misunderstanding lies at the core of the 
arguments posed by those who are against gene patents where gene patents have wrongfully 
been assumed to allow individual companies to own the entire human genome.128 This is not 
the case according to Haseltine, instead the genes which are patentable are single artificially 
synthesized genes which are used to create new medicines and develop pharmaceutical 
research.129 The point which Haseltine tries to clarify is that there appears to be an ethical 
confusion in the current debate where genes are assumed to be interchangeable with life. 
Haseltine tries to clarify this miscomprehension by expressing that a patentable gene is 
something completely separated from the human body and that this by extension means that 
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gene patents do not pose a threat, instead it will stimulate research which will be of great 
benefit to many. 
David B. Resnik, a specialist in bioethics at the National Institute of Environmental Health 
Science in the US,   follows a similar line of argument where he argues that owning the entire 
genome might pose as a risk to human dignity but that owning specific genes does not. He 
also argues that ownership of the entire human genome is something highly unlikely and thus 
does not pose as an actual threat to humanity.130 Since the unveiling of the results of the HGS 
???????? ??????? ???????????????????????? ??? ?????? ????????? ???????????? ???????????????? ??????
this entails that gene patents should be admissible as they do not constitute a threat to humans.  
6.1.3 Patents do not inhibit scientific development 
One concern which has surfaced is that allowing gene patents will actually result in a less 
effective and decelerated research capacity. The logic behind this concern is that when gene 
patents are awarded to single pharmaceutical companies the remaining research companies 
will be locked out of using that particular gene thus making it impossible for other companies 
to continue researching on that particular gene. Timothy Caulfield, the Canadian Research 
Chair in health and law policy, states that there is actually no evidence supporting that gene 
patents would lull the advances of research.131 Notably about 20 % of the human genome is 
patented132 but in a US survey from 2005 the national academy for science found that only 1 
% of projects were delayed more than one month due to complications with patents.133 This 
result may appear to present a situation where gene patents are not in fact a problem for 
????????????????????? ???????????????????????????????????????? misleading due to that research 
companies may merely chose not to continue their projects once they have found that the gene 
is patented. Since the report merely presents delays and does not actually deal with cancelled 
or not pursued projects this report in itself may not actually paint a fair picture. However, in 
2007 the American associate for the advancement of science found there to be ?????? ???????
????????? for that IP protection should impede scientific research.134 In all Caulfield argues 
that it is not logical to assume that gene patents lock out potential researchers, however, 
depending on how the results are interpreted, this point of view may not be completely fair. 
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6.2 Arguments against gene patents 
Since the topic of gene patents was introduced it has been a very controversial issue. There 
are many different groups of people who fear the repercussions of the judicial change which 
legalizing gene patents entails. This section of the essay will focus on the arguments posed for 
limiting or removing the ability to patent genes. 
6.2.1 No one can claim ownership to the human body 
One of the most fundamental arguments which has surfaced in this debate concerns ownership 
of the human body. It seems as though one of the greater fears attached to gene patents is in 
??????????????????????????????????????????????????????????????????????????????????????????????
bodies.  
One of the instances which argue against gene patents on the grounds that it should not be 
possible to own a part of the human body is the Swedish National Council of Medical Ethics 
(henceforth called the council). The council sent their opinion on the directive to the Swedish 
department of Justice in 2002 and herein they explain that the possibility of claiming 
ownership of the human body should not be possible.135 One of the fears that the council 
expresses is that the patentability of genes risks limiting research and hindering health care. 
The Council express great opposition to the implementation of the directive on the ground 
that monopolizing the human body and affecting access to health care negatively is 
unacceptable. 136 
6.2.2 Increased costs  
Pre-directive saw the enforcement of highly aggravated farmers who were arguing that the 
directive would result in higher prices and lower incomes for the individual farmer. The fear 
behind this discussion is that biotechnical advances within agriculture will be too expensive 
and therefore not available to the smaller farmers with less money137 which risks resulting in 
smaller farmers being less competitive due to the fact that they cannot access modern 
agricultural technologies. By extension this risks meaning that smaller farmers would be 
forced out of the agricultural sector. In a report on the effect of gene manipulated crops in less 
developed countries it is presented that the prices of the seeds for gene manipulated crops are 
very high and that the price is related to the number of years which the patent is upheld in a 
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country.138 The patents on genes in the agricultural sector can be used as a means of locking 
single farmers out of new technologies that larger competitors can afford and thus will have 
access to.   
It seems as though at least part of the prospective effect on agricultural products has become 
true as reports on raised seed are readily found139 and record revenues for agricultural 
companies are reported.140 
6.2.2.1 Myriad genetics 
The concern for increased costs presented in the previous section can also be applied to 
discuss gene patents for pharmaceuticals. The company Myriad Genetics has held the patents 
in Europe for human breast cancer and ovarian gene called BRCA1 and BRCA2 since 2001 
and 2003 respectively141 and in the US since 1997142. Myriad produces a test which shows the 
patient whether they are a carrier of the breast and ovarian cancer gene costs $3340 per test in 
the US rendering it virtually inaccessible to many.143  
In the US the patent held by Myriad genetics has raised a huge debate on the admissibility of 
??????????????????????????????????????????????????????????????????????????????????ceuticals. 
The debate was instigated when Genea Gerard was diagnosed with breast cancer in 2006. She 
was then tested to see if she was also at risk of developing ovarian cancer and the test result 
was positive displaying a high risk of developing ovarian cancer. Genea then wanted to take 
another test in order to get a second opinion but her insurance company refused to pay for it 
on the grounds that it was too expensive.144 The test was based on the gene patent which was 
held by Myriad Genetics. Joined by other cancer patients and organizations, amongst others 
the American Civil Liberties Union (ACLU) Genea filed a lawsuit urging the courts to 
remove Myriad Genetics patent. The ACLU later expressed in a press release that they had 
filed the lawsuit because: ?Gene patents undermine the free exchange of information and 
????????????????????????????????????????????????????????.145 
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In federal court the patent was revoked on the grounds that the judge found that patents on 
genes are against the laws of nature146 However in the court for appeals for the federal circuit 
the patent was upheld where the courts argued that isolated DNA is something separate from 
the DNA which is found in the human body.147 Thus the court of appeals adhered to the ruling 
of the Supreme Court in the case Diamond v Chakrabaty allowing for continued patent 
protection for genes. If the ACLU and other plaintiffs will appealed to the Supreme Court is 
uncertain at this time.  
Patent litigation is not an unusual concept but the norm is that the process revolves around 
infringement or third parties claims that the patent does not fulfill the criteria for patentability.  
Instead the Myriad genetics case is a law suit which deals solely with the accessibility to 
medicines and the hindrance that gene patents result in with regards to access to medicines. 
The case is thus not a case dealing with infringement or unlawful patents but instead this case 
is in regards to policy.148 
6.2.3 A gene does not fulfill criteria for patentability 
As mentioned earlier a product has to be industrially applicable, new and inventive in order to 
fulfill the criteria for patentability. During the implementation of the directive and throughout 
EPO case law the criteria for patentability have been expanded in order for genes to fit into 
the mold of what has previously been patentable. Some, however, argue that this expansion is 
too wide and that including genes in patents means that one has removed the criteria required 
of a patentable object.  
What is often argued is that genes in patents are far from what occurs in nature since the gene 
has been so far synthesized that it can no longer be compared to what occurs naturally. 
However, others argue that what is actually changed about the gene is that useless information 
in the form of un-coding introns149 is removed which actually only changes the appearance of 
the gene, and not the function in itself.150 This means that removing some introns does not 
make the gene new or non-obvious thus not fulfilling the basic criteria for patentability. 
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6.2.4 Gene patents hinder research 
One of the strongest arguments against gene patents is in regards to its effects on research. 
Some fear that allowing these patents will make research more costly and less efficient due to 
the monopoly on certain genes and the need to form licensing agreements before using a 
patented gene in research.151  
In a US survey from 2003 53 % of leading laboratory directors said that they chose to not 
pursue a certain area of research due to risk of patent infringement.152 In the same survey 25 
% of laboratory directives said that they had received notification from patent holders to 
resume from performing research in a specific field.153 These results are hardly surprising 
considering that a report from 2005 shows that over 20 % of the human genome is patented in 
the US.154 These results show an almost inevitable clash between patent holders and 
researchers where the patent holders wish to protect their patents while researchers and by 
extent, the public, might find it more beneficial if genes were accessible to all.  
7. The Monsanto case 
7.1 Background: Monsanto history 
Monsanto is an American agricultural company which has existed in its current form since 
2002.155 ???? ?????????? ???????? ?????? ????? ??? ????? ???? ??????? ??? ????? ??????????????????
created from the agricultural division of the Swedish-American company Pharmacia.156 
Monsanto is a considerable corporation with facilities all over the world.  
Monsanto has been notorious internationally for many years. For instance; Monsanto was one 
of the companies which supplied the American army with Agent Orange during the Vietnam 
War.157 
??? ?????? ???? ??????? ??? ????? ??? ??????????? ????? ??? ???? ????? ??? ?????????? ????? ??? ?????
Monsanto placed as number 234 on the Fortune 500 lists.158 This list is compiled annually by 
the Fortune magazine and depicts the 500 companies with the largest gross revenue.159 
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Since 2002 the reformed Monsanto has focused solely on agricultural products. Within the 
area of agricultural products Monsanto are well known for creating crops which are more 
resistant to pests and which grow more voluminous then regular crops, simply put Monsanto 
has focused a lot of their business on creating Gene Manipulated Organisms (GMO).160  
7.2 Background: the case 
Monsanto has held a European patent for a gene sequence that makes soy beans resistant to 
pests since 1996; the system is named Roundup Ready by Monsanto. This gene has been 
introduced into soy beans and sold throughout Argentina for several years, notably however, 
Monsanto did not hold a patent for the gene sequence in Argentina. During 2005-2006 flour 
produced out of this soy bean was imported into the Netherlands.  
Monsanto requested that tests be performed in order to determine if the flour contained the 
genetic materials for which they held the patent in Europe. After testing it was concluded that 
the soy flour contained segments of the DNA which Monsanto had patented. 161 
Monsanto brought the case to court in The Hague and this court referred the question about 
the extent of a genetic patent according to the biotech directive to the European court of 
Justice (ECJ).162  This case is interesting partly because it is the first case within the scope of 
biotechnology which has been brought to court since the directive was implemented but also 
because this case focuses on the scope of protection for gene patents in deviation for the norm 
of European case law which focuses on criteria for patentability. 
7.3 The ????? verdict 
The Dutch courts referred four questions163 to the ECJ: 
1. Is article 9 of the directive to be interpreted as providing protection for a genetic 
sequence even when that genetic sequence no longer holds a function in its current 
state but may possibly perform a function again if extracted and inserted into another 
organism? 
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2. Does article 9 in the directive lead to a hinder in allowing absolute protection of a 
genetic material according to national law independent of if the DNA is performing a 
function or not and is article 9 of the directive exhaustive in this situation?  
3. While answering question 2; is the fact that a patent was granted before the directive 
was adopted have any relevance when an absolute product protection was in place 
according to national laws? 
4. Is it possible to regard the TRIPS agreement and particularly articles 27 and 30 while 
answering the above mentioned questions? 
7.3.1 Question 1 
Article 9 of the directive states that:  
?The protection conferred by a patent on a product containing or consisting of genetic 
information shall ?????????????????????? in which the product in incorporated and in which 
the genetic information is contained and performs its function.?  
During its ruling on this question the court takes a very literal approach towards the wording 
in article 9 of the directive. The court notes that the use of present tense in article 9 of the 
directive ????????? ????????? should be interpreted as an indication of that the function of 
the DNA has to be active if Monsanto should be able to claim that an infringement in their 
patent rights has taken place. The court also concludes that an herbicide is without function 
once the soy bean has been transformed into flour.  
The fact that the DNA sequence could be extracted and implanted into another plant where it 
can perform a function is not in itself a fact that lives up to a violation of article 9 of the 
directive. However, if the DNA was to be extracted and implanted into another biological 
material the courts do not deny that this will give rise to a situation where an infringement 
could take place in regards to the patent and the new biological material.  
Furthermore the court points towards the limitation in article 23 of the preamble to the 
directive where it is stated that a DNA sequence which does not hold a function cannot be 
protected via patents. Moreover article 5(3) of the directive holds the same intention that 
genetic sequences lacking in industrial applicability cannot be awarded patent protection. 
Article 23 of the preamble, article 5(3) of the directive and article 9 of the directive in tandem 
mean that a DNA sequence which does not hold a function cannot be awarded patent 
protection.  
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The court thus concludes that a DNA sequence which does not hold a function in its current 
state cannot be awarded patent protection independent of if the product could be extracted and 
placed into another organism where it once again would serve a function.  
7.3.2 Question 2 
The court answers question 2 by reviewing the preamble to the directive. Firstly the court 
points towards recitals 3, 5 and 7 in the preamble to the directive. Herein it is stated that it is 
necessary to create harmonized legal protection for genetic inventions to encourage 
investments in this field and that the lack of harmonization which existed risked creating 
barriers to trade. Collectively the above mentioned recitals point towards the need for 
harmonization in order to encourage trade on equal terms within the European Union.  
Furthermore the court views recitals 8 and 13 in the preamble to the directive where it is 
stated that there is no need for the member states in the European Union to create a separate 
law regarding biotechnical patents and that the national law remains the basis of patentability 
pending that they adopt their laws to conform to the directive. The recitals also state that the 
??????????????volvement can be limited to certain principles. From recitals 8 and 13 it can be 
concluded that the European parliaments aim with this directive was to harmonize the 
member states legislation without interfering in the material law in any separate member state. 
The court stresses that the aim of this directive is to harmonize the member states legislation 
in order to remove barriers to trade and optimize the balance between patent holders rights 
and others. Whilst stating that the directive wants to enforce minimal changes on the member 
states the courts also point towards article 1(1) sentence two which requires nations within the 
community to change their legislation in compliance with the directive.  
The court concludes that because of the above mentioned, member states may not include 
infringement rights under unlimited protection to genetic material when the gene does not 
perform a function; article 9 of the directive is exhaustive.  
7.3.3 Question 3 
The court answers this question by referring to the case Commission v Freistaat Sachsen164  
and in this case the courts refer to Brock165  and Licata v ESC166 where it was settled that old 
rules are replaced by new legislation regarding future settlements.  By referring to these cases the 
courts hold on to this well established principle which over-rides old legislation to allow 
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consistency throughout an entire legal system. If the courts were to treat different patents 
differently depending on when they were registered the system would become too complex to 
uphold. New legislation would also become very difficult to enforce if those rules were not 
applied to registered patents since this would mean that it could take up to 20 years until the new 
rules were applied on all registered patents. 
The court clarifies that the directive does not allow for any deviations and that if different patents 
were to follow different rules then this would lead to a hinder in the harmonization of the member 
states legislation regarding biotechnical patents.  
The court concludes that the fact that a patent was registered before the nation signed the directive 
does not allow the patent holder absolute protection as it was structured under national law at the 
time when the patent was granted.  
7.3.4 Question 4  
To clarify, the court starts by stating that the TRIPS agreement does not give individuals 
rights which can be brought before the court which has previously been stated in the cases 
Dior and Others167. However, it is also pointed towards that even if there is EU legislation in 
place then that rule shall be viewed in the light of the TRIPS agreement in accordance with the 
case Merck Genéricos - Produtos Farmacêuticos.168 The directive is to be considered 
European Law and should therefore be interpreted while keeping the TRIPS agreement in 
mind.  
Article 27 in TRIPS declares which areas should be subjected to patentability and article 30 
states exceptions to the rights attached to patents.  In this case the court chooses to interpret 
???????????????????????????????? in article 30 as harboring both exceptions to right as well as 
limitations to these rights. By this logic the court finds that article 9 of the directive is 
compatible with articles 27 and 30 of the TRIPS agreement.  
8. Developments so far 
As mentioned above the directive was intentionally left unspecified in order to allow the 
separate member states to formulate their own interpretations of the directive. Its objection 
was to harmonize European patent law and to create financial incentive for corporations 
researching on genes. However, by merely creating a frame work and leaving the legislative 
duties to the member states the European Parliament also created many areas of unclearly and 
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loss of structure. If the aim was to harmonize European patent law the question is if the best 
way of doing this was really by implementing such a vague directive?  
It might seem as though the initial assumption regarding the gene patents was that the rights 
conferred were virtually unlimited.  However, as has been discussed above, there are factors 
which have left the scope of patent protection diminished. The question which will be focused 
on in this chapter of the essay is the scope of patent rights and how the Monsanto case has 
affected the judicial status of genetic patents. 
8.1 A balanced system? 
A patent has dual functions; on one hand a patent allows the inventor and patentee the right to 
protect their investment and invention and on the other hand a patent also allows the 
spreading of information, facilitate access to information and encourage research.169 The 
purpose of the patenting system is to create a balance between financial investments, 
innovation and access to new technologies at a reasonable cost.170 The aim of the patenting 
system is that an invention should be protected but at the same time the public has the right to 
access the information in order to utilize it after the term of protection has elapsed.  
Acquiring absolute patent protection for a gene is slightly different from what is discussed 
above. As has been mentioned earlier an absolute patent protection entails an expansion on 
the normative scope of protection where the scope of protection is not limited by the current 
invention and use of that invention but also includes areas of application which may not be 
known when the patent application was filed. 
Even though possibilities like licensing and compulsory licensing are available it is necessary 
to reflect upon if the system concerning gene patents is actually balanced. The question of if 
the rights assigned by the system actually match the scientific achievement of purifying a 
gene arises. Since the rights attached to gene patents are vast many would argue that the 
protection within this form of patent is too extensive. One must remember that allowing 
patent rights for genes was, and is still, disputed and by allowing such an extensive portfolio 
of rights the regulations might be found to be too generous. Even if the ethical elements of 
allowing gene patents were ignored the question of if the genes constitute a patentable matter 
still remain where many argue that discoveries should not be patentable since this extends the 
patent system too widely and thus supersedes the established constraints of patents.  As has 
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been mentioned before many biotechnical companies and others who are pro gene patents 
argue that that genes do not constitute mere discoveries as the matter is greatly purified before 
being up for patentability. However the subject is highly volatile and adding an extensive 
protection system could also be questioned and cause those who are displeased with the 
system to gain fuel for the fire. The reader must remember that allowing absolute patent rights 
for genes was allowed in order to mimic the protection allowed for chemical compounds; 
however this is not necessarily the obvious and most successful choice for this type of 
element. Instead, it might be more natural to limit the scope of the patent to only include the 
proteins which are listed in the patent application. Fundamentally there is a difference 
between allowing one type of protection for a chemical molecule which has been developed 
in a lab and allowing that same protection for a gene which exists naturally. Even though the 
process of synthesizing genes and developing chemical compounds might be similar 
regarding the labs technical work there are several more factors that supersede financial 
investments which should be considered. 
Regarding the rights inferred by the directive it is difficult to find the actual limits of the 
absolute protection of genes as these are continuously tested in court. The development 
through case law will probably continue for a long time before the limits to gene patents and a 
balanced system can be crystallized.  
8.2 The interlink of the US and EU 
In order to clarify the background to the directive and the mood in which it was launched it is 
important to note the development of the law concerning biotechnical inventions. The 
development which lead to the directive did not start in the judicial arena but instead in the 
administrative arena via patents allowed by courts in the US (see Diamond v Chakrabaty) and 
by the EPO in Europe. It seems as though the legislative arena has followed the administrative 
which might be an indication of that the development is not thought through but is instead 
forced by biotechnical companies.171 As has been mentioned earlier the directive was 
introduced largely as a result of the financial interests of agricultural and pharmaceutical 
companies in the US in order to assure the development of investments and research by these 
institutions. The development within the US was later followed up in Europe by the case law 
of the EPO. However, it is important to acknowledge that the EPO is not a part of the 
European Union but is an independent administration concerned solely by the protection and 
development of European patents. The European Parliament then followed suit by introducing 
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the directive in order to harmonize European patent law and to strengthen the position of 
biotechnical patents in Europe.  
The judicial development within the US and within the EPO basically left the European 
Parliament without the possibility of choosing to harmonize the member states legislation via 
the directive. In order for Europe to remain competitive with the US within biotechnology the 
EU had no choice but to empower European pharmaceutical companies with the ability to 
patent their genetic discoveries through the member states national law. 
??????? ???? ??? ???? ??????? ???? ???????????? ??? ????????? ??? ??????????? ???? ????? ?????y as 
established or organized as it is in the US. In the US lobbyists are protected under the US 
??????????????? ?????? ?????????? ??? ???? ?????? ??? ????? ???????? ????????? ???? ???? ?????? ???
petition.172 Lobbyists give testimonies and provide information to the congressmen and 
women who later chose to vote to stop or pass a bill. The ability to provide the congressmen 
and women with information and supply testimonies from experts is largely dependent on 
large funds. For example drug and pharmaceutical companies were estimated to have spent 
$110 million in the half of 2009.173 This entails that large pharmaceutical companies with 
large funds will be able to have their voices heard to a much larger extent then a non-profit 
organization trying to voice the ethical debate on gene patents to congressmen or women. The 
system of lobbying seems unjust in the sense that the depth of the pocket becomes equal to the 
strength of voice with regards to new legislation or support of praxis like in regards to genetic 
patents. It is important to keep in mind that companies who research genes are, in many cases, 
some of the largest and financially strongest corporations in the world.  
As Europe was driven to follow the US in order to allow European Pharmaceutical companies 
the chance of keeping up with developments in the US the question remains: was the 
permission of gene patents really the best option or was the hand of the legislator too 
influenced by strong financial interests? 
8.3 The effect of the Monsanto case 
After the case was settled Monsanto, via a press release on their web site, stated that the aim 
??? ???? ?????? ???? ??????? ??? ????? ???????????? ?????????? ???? ???? ?????? ???????????
technology for free.174 ????????????? ?????????????????????????????????????????????????????????
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could not be enforceable on products where the gene does not have a function, which it did 
not have in this case. If the gene is merely present in the product but does not actually perform 
a function the courts interpreted that the directive does not encompass the basis for an 
infringement claim. 
The ruling has been interpreted as showing a clear support for gene patents while stating that 
the directive should be interpreted narrowly in cases like these.175 ????????????????????????
over-reach of the scope of patent rights in this case. However, what becomes interesting is 
that the limits applied by the courts was not apparent before the case even though some have 
stated that the ruling was not surprising176 this case is the first clear statement issued 
surveying the limits ????????????????????????????????????????????????????????????????????????
of 13 members which signals that this judgment was one of great interest and importance to 
the development of gene patents within the EU. Interestingly the Dutch importer and 
Monsanto had come to a settlement before the case came to court but the ECJ chose to fulfill 
the proceedings and pass judgment.177 By issuing a verdict even though the case was settled 
the ECJ display that there is s need to crystallize the limits to the scope of gene patents in 
order to create a more predictable and stable environment for gene patents.  
The effects of the ruling could be that there is an increase of imports of processed products 
from countries with weak patent systems.178 This does risk resulting in the courts actually 
legitimizing countries outside of Europe, with patent systems which are not equal to the ones 
within the EU, to flood Europe with cheaper products. Even though the aim of the directive 
was not explicitly to hinder this development it is unclear if the risk of encouraging countries 
without the same level of gene patent protection was calculated by the ECJ. The risk might 
not be overwhelming but the implication could be interpreted as encouraging European based 
corporations to produce crops and process them outside of Europe in order to import them 
into Europe when the DNA has reached a stage where it no longer performs a function. This 
could result in agricultural companies relocating their production outside of Europe in order to 
avoid paying licensing fees to companies which hold the patents. It is however important to 
note that no such developments has yet been observed. 
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8.4 Summary 
As has been discussed above the directive was enforced in order to allow the European 
biotechnology to compete with the US industry. The basis for introducing genetic patents in 
the US was undoubtedly financial where pharmaceutical and agricultural companies had a 
strong influence on the current legislation. In order to reach the level of protection applied to 
US gene patents and thus compete within the same realm the scope of protection for gene 
patents must be equally strong within Europe.  
The result of the parliaments strive to compete with US and EPO case law has lead to a patent 
protection which is so strong that it extends beyond the goal of a balanced patent system.  The 
absolute patent protection allows for a very broad protection and it seems that the voices of 
those opposed to gene patents were not adequately considered while creating this patent 
system.  
Due to the fact that the directive has been formulated so openly this has lead the European 
member states without clear directives on how to delineate gene patents. The extensive 
protection awarded by the US and EPO have also affected the scope of protection of gene 
patents. The judgment in the Monsanto case awarded Europe with at least one clear line 
drawn: when the patented material is no longer functional the scope of protection does not 
include this state of DNA. Even though some argued that the judgment on the case was 
obvious it is important to note that with these types of judgment come clearer limitations on 
the scope of rights attached to genetic patents. Through this judgment the ECJ clarify that 
even though the concept of gene patents is still upheld its realm of protection is not without 
limits.  
9. The future 
Predicting the future of gene patents may appear to be a precarious exercise. However, the 
fact that the law tends to develop at a much slower rate than technology makes predictions 
beneficial. This argument rings especially true when the field of biotechnology is discussed 
since this is a market which generates enormous revenues and which thus has the capacity of 
developing at a very fast pace. This can mean that the laws which were designed for a type of 
gene patents are soon applied to developments which the law was not originally designed for. 
The fast pace of research development in relation to the slow evolution of laws makes for an 
area which is greatly in need of predictions for the future.  
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9.1 Important advances 
As was mentioned earlier in the essay the possibility of patenting genes has been a reality 
since the 1980s when the US court upheld the first patent on a GMO in Diamond v 
Chakrabarty. This case became a landmark and soon the possibility of patenting genes was a 
reality in Europe via the EPO.  
The first years of gene patents saw for a flooding of patent applications into the patent offices. 
During the period 2001 to 2003 there were two great developments which altered the field of 
European gene patents. The first change was the EPOs ruling in the ICOS case where the 
possibility of patenting genes saw a heightening of the criteria for industrially applicable. This 
case saw the EPO raise the bar for the information which was required to be provided in the 
patent application demanding a specified area of use instead of a more speculative area of 
application. The second change was provided by the HGS project which was completed in 
2003. This project presented a mapping of the human genome and with its unveiling came a 
raised bar for patenting human genes. Even though the HGS project only concerned human 
genes it has had a considerable impact on the area of gene patents as many of these types of 
patents are regarding human genes. As a result of the two mentioned incidents gene patent 
applications have been said to decrease greatly.179 The result has been that patentees are more 
careful in their patent aspirations waiting longer before they patent because they are aware of 
the raised demands of patent applications.  
Herein it is also relevant to note that there are a finite number of genes which can be patented. 
This means that even though the HGS project and ICOS case had a great effect on the ability 
to patent genes the diminishing amount of patent applications are natural due to the fact that 
there is simply a steadily diminishing pool of genes which fulfill the criteria set up by the 
directive and the EPC. It may be that the HGS project and ICOS case caused the rate of 
decrease of patent application to be brought nearer in time but the development would have 
happened at some point in the future due to the nature of genes.  
9.2 Conclusions on the case Myriad Genetics  
It is appropriate to discuss certain developments within US case law since it was the US who 
introduced the acceptance of gene patents which Europe then followed through the EPO and 
the directive. It is important to note that Europe, in order to be competitive within the field of 
biotechnology, is and has to be influenced by the developments in the US. 
                                                 
179 Engineer Patrik Andersson at the Swedish Patent and registration office states this in a phone 
interview/discussion 2011-11-21. 
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When gene patents were first allowed in the US in the 1980s the patent office was flooded 
with patent applications on genes. In 1999 the United States Patent and Trademark Office 
(USPTO) released stricter guidelines180 regarding gene patents. These guidelines state for 
example that: 
?If at any time during the examination, it becomes readily apparent that the claimed invention 
has a well-established utility, do not impose a rejection based on lack of utility. An invention 
has a well-establ????????????????? ????????????????????????????????????????????????????. 181 
The EPO have not directly followed suit by addressing these demands within the EPC but 
through the ICOS-case the EPO seem to fall in line with the USPTOs guidelines since the 
EPO also require that the patent application needs to have a specific area of industrial 
???????????? ???? ??? ?????? ?????????? ????? ??????????? ???? ???? ??????? ?????????????? ???????????? ???
constantly affected by US developments within the area of gene patents.  
The case Myriad Genetics has already been discussed but the repercussions of the case and 
how it may influence the future for gene patents has so far been overlooked. The Myriad 
Genetics case can be seen as an uproar towards the strength of gene patents directly affecting 
the human health as large organizations like Association for Molecular Pathology, American 
College of Medical Genetics and American Society of Clinical Pathology alongside several 
individuals182 filed the claim against Myriad demanding that the patent be revoked. This case 
has given fuel to the fire on the debate on human gene patenting183 and the effect which is 
withholding access to health care due to high prices which are a result of the patenting system. 
Many individuals and organizations simply find that genes should not be patentable and 
looking at the development of stricter criteria for patents the laws appears to agree with the 
naysayers. The fact is that the patentability of genes is based on a legal construction where the 
term invention is defined differently than how it is used in everyday language. The 
patentability of genes may be too abstract for the general public to accept which can be seen 
as the reason to why the debate on patenting genes has been current for such a long time. The 
ability to patent genes has been available for thirty years yet the public and several legal 
????????????????????????? ??????????????? ????????????????????? ??????????????????? ?????????? ???
note with regards to the debate which has been fuel by the Myriad case in the US is that it not 
an accepted system of patenting which can be deducted on the basis that partly the media 
                                                 
180 USPTO Guidelines for Examination of Applications for Compliance with the Utility Requirement. 
181 Section II A (3). 
182 Case 09-cv-04515. 
183 For example Anderson, h+ magazine October 26 2009. 
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storm which has occurred as a result of this case and the fact that the judge in first instance 
ruled the patent to be invalid.  
Notably the US Government submitted an Amicus Curiae184 brief stating that their view was 
that isolated but otherwise unmodified genes should not be patentable since they should not 
be considered inventions.185 This entails that patenting genes is not a system which is 
fundamentally supported throughout the public or throughout the judicial system.  
Within the scope of the Myriad case it has also been argued that the expensive tests provided 
by Myriad Genetics could be provided more efficiently and a lower cost in an open market.186 
One of the main arguments for gene patents is the incentive to research which can be counter-
argued by the high product prices which arise when only one company produce a product. It 
may be that merely viewing gene patents as an incentive to research is too simple and instead 
the legislator should also consider the aftermath of awarding monopolies on genes. The result 
of gene patents could be that it encourages primary research but then stifles development 
within the patent which has been awarded. It??????????????????????????????????????????????????
which has people and organizations angered and fighting back. As mentioned before the US 
and Europe are interlinked which results in ripple effects on debates taking place in the US 
which then soon reach Europe. This may result in a re-fueling of the debate on the extent of 
protection on gene patents in Europe as well.  
9.3 Conclusions from the Monsanto Case 
Even though the outcome in the Monsanto case may not have been unexpected the case falls 
in line with a number of legal and administrative measures taken in order to limit the 
distribution and scope of protection for gene patents. Since the area of gene patents is 
relatively new it is constantly developing which means that we will probably see cases in the 
future which may seem apparent but to which the legal sphere cannot offer answers to prior to 
???? ???????? ????????????? ??? ??????????? ?????????? ????? ????? ??? ????? ???? ???????????????? ??????
administrative and legal aspects, fends back the scope of gene patents when those in 
possession of gene patents try to expand the scope. In relation to the scope of patent rights it 
may be appropriate to quote Baron Acton ??????? ?????? ??? ????????? ???? ????????? ??????
                                                 
184 Amicus Curiae briefs are briefs containing information which are submitted to the courts by someone who is 
not a party in the trial. 
185 Amicus Curie Brief by the US Government www.genomicslawreport.com/wp-
content/uploads/2010/11/Myriad-Amicus-Brief-US-DOJ.pdf p. 17f accessed on 2011-11-25. 
186 Pollack (I), New York Times 24th August 2011. 
 49 
corrupts absolutely. Great men are almost always bad men?.187 This quote may seem 
misplaced within the realm of this essay but the point is that there is a need for powerful 
companies patents to be controlled as Lord Acton says in his famous quote, otherwise they 
will aim to expand the scope of patent rights as far as possible. Monsanto is a vastly powerful 
company as are many companies which are in possession of gene patents.  
?????????????????????????????????????????????????????????????????????????????????????????????????
to expand the scope of their gene patents.  As the area of gene patents is developing quicker 
than the laws it is important for administrative arenas and judicial arenas to cooperate in order 
to restrict that development in order to strive for a balance between invention and protection 
within the patenting system.  
9.4 Future within biotechnology 
The legislation may find the case law and legislation which has developed within this area 
may be considered adequate for the type of research which is possible today. It is, however, 
important to note that science tends to evolve quicker than the law and that the scientific 
community benefitting from research have great resources to develop beyond the realm of 
what is scientifically possible today. Most of the administrative and judicial developments to 
gene patents are in relation to higher demands on the criteria to patent which might be 
inadequate considering the biotechnical progress which is within grasp.  
Section 2.2.2 mentioned the ability to apply gene therapy in order to exchange a diseased gene 
with a health gene and thus eliminate a genetic disease in a person.  Currently zygotic gene  
therapy is not conducted or allowed on humans, however, the thought of being able to 
permanently change a feature on oneself which a person does not wish to pass on to its 
children will probably seem appealing to many. The reader should also be aware of the fact 
that zygotic gene therapy is not limited to being applicable in case of genetic diseases it could 
also be used in more superficial cases to example change th???????????????????????????????????
cosmetic feature of a person. The skeptic might point towards the fact that many physical and 
mental characteristics are dependent on several genes in combination with the environment; 
however, there are trials in animals which have displayed the effect of altering single genes. 
For instance a gene was changed in a fruit fly followed by adding a certain chemical to the 
?????????????????????????????????????????????????????????????????????????????????????????????????
                                                 
187 Acton, letter to Bishop Mandell Creighton in 1887. 
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gene had not been changed.188 Another illustrative example is that scientists believe they have 
found a gene where carriers become tone deaf.189 The problem which arises is that the future 
holds a limitless possibility to change the genome. There are many prospective parents who 
would most likely be prepared to pay large sums to guarantee that their children do not carry 
genes coding for Alzheimer or on a lighter note: tone deafness. Where there is a paying 
market there is also research companies lining up to develop a product which will generate 
revenues.  
There are alterations which can be made to animals and people which could enhance physical 
and mental performance. The point is that it already, at least theoretically, lies within grasp to 
provide individuals with a more powerful genome which ultimately could mean that gene 
patents would provide certain pharmaceutical and agricultural companies with a heightened 
power. This prospect may be compared to the earlier mentioned Eugenics movement which 
had dire consequences for many. The Eugenics movement was a crude attempt at gene 
therapy but is important to recognize that the tampering of genetics in order to create a 
stronger race is something which has existed for over 100 years and which is fascinating to 
many.  As has been mentioned before the patenting system is meant to provide incentive to 
research but allowing for a higher level of protection and thus a higher level of profit may 
cause incentive to develop genes further than many people realize.   
9.5 Summary 
The development of gene patents so far appears to be a slow but steady decreasing of when a 
company can apply for a patent and its corresponding patent rights. Due to several aspects, 
discussed above, the gene patent scope has decreased and it has become increasingly difficult 
for research facilities to gain a gene patent. The future will most likely entail future 
developments in this direction where patentability of genes will continue to be limited by the 
outcome of the ICOS case and the developments through the HGS project. It seems highly 
unlikely that the EPO or USTOP should be willing to reverse the development and aim to 
facilitate gene patenting further since this would mean going against a growing public 
opinion. As was mentioned above the Myriad Genetics case has gained great media coverage 
which will form public opinion, irrespective of the accuracy of the articles they still have 
great effect on public opinion on gene patents.190  As laws are supposed to be a codification of 
                                                 
188 Brändén, Genteknik, kloning och stamceller p. 94. 
189 Ibid. p. 96. 
190 Morrisson, Biotechnology Law Report 2010 p. 609. 
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societies morals and ethics it would most likely be too risky to change the restrictive 
development of gene patents which has been occurring during the last ten years.  
As a result of the media coverage of the Myriad Genetics case the ??????????? Advisory 
Committee on Genetics, Health, and Society ordered a study to be carried out by Duke 
University aiming to result in an answer to the question: are gene patents beneficial to 
research?191 The report concludes that the application of gene patents is too broad which, in 
some areas, stifles research instead of encouraging it.192 This report is interesting because the 
incentive to research has been the strongest argument for gene patents, but instead this report 
says that in certain cases the gene patent system actually harms progress.193 The report is still 
relatively new which means that the aftermath of its results are not possible to view yet but 
the chance is that this report may stifle one of the main pro-patent argument placing a new 
light on the discussion of the scope of protection of gene patents.  
It was hardly reasonable to expect the higher courts of justice to render Myriads patent on 
genes unlawful because this type of decision would have great repercussions by throwing the 
legitimacy of gene patents into uncertainty. If the courts wish to restrict gene patents further 
this development will most likely be performed more gradually.  
From articles discussing the Myriad Genetics case it seems as though many still favor the 
human rights aspect of the gene patent debate arguing that genes should be accessible to 
people. A popular point of view is that individual pharmaceutical or agricultural research 
companies should not be able to own a certain gene resulting in isolating humans from access 
to effective health care or optimizing crop growth. This point of view is in line with Tauri?s 
theory on critical legal positivism where gene patents are a relatively novel concept which has 
not had time to sediment through the layers of the law and reach the same status as human 
rights has. 
The reader should be aware of the openness which remains in the gene patent system today. 
An absolute product protection is available for those who meet the criteria which leaves the 
floor open for companies to develop genes where there are not currently exceptions in the 
law. The gene patent system is, at least in theory, an unbalanced system allowing for a greater 
realm of protection in proportion to the discovery made. Even though the system may appear 
to be relatively balanced today it is imperative to watch the horizon for gene developments 
                                                 
191 R Cook-Deegan & Heaney, Genetics in Medicine 2010 supplement p. 1. 
192 Greenemeier, Scientific American 2010. 
193 Evans, Genetics in Medicine, 2010. 
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which may be applied to gene patents allowing the patentee a large scope of protection. The 
gene patent system is relatively new and according the theory on critical legal positivism 
sedimentation is slow, however, if the future is to hold a balanced patent system for genes 
then the changes to the legislation need to be enforced at present in order to allow the changes 
to graduate throughout the system to settle in the deep structure of the law.  
10. Conclusions 
From the beginning of gene patents it was assumed that the best way of providing incentives 
to private research institutions was via allowing the patenting of genes. This argument has 
then followed the debate on gene patents and has always been fronted as one of the main 
incentives to the continued patenting of genes.  The truth is that the argument is highly valid 
as the price tag on biotechnology is staggering. The biotechnology industry needs private 
investors in order to maintain research and in their turn these investors need assurance that 
their investments are protected.  
In contrast to the financial incentives in biotechnical companies are the interests of 
individuals. It has long been assumed that patenting genes is necessary in order to ensure 
biotechnical progress. This biotechnical progress would then directly benefit individuals in 
the form of new advancements. Currently this assumption seems to be somewhat too 
????????????????????????????????????????????????????????????????????????????????????????????????
actually differentiate between the use of different forms of gene patents and award different 
scopes of rights for different areas of application. The impact that the report will have on the 
patenting system is yet too early to determine. It is, however, clear that the report presents a 
view which has so far been overlooked leaving the system of patenting gens undiversified. 
Even though the Duke report entails that a more diversified system of gene patents may be 
scientifically efficient it does not provide an answer to how the system should be changed. As 
was noted in the Swedish Official Reports, the patent system is notably unbalanced but trying 
to create a more balanced system would be practically difficult and very costly thus not 
constituting a viable option.  
There is an important point to be made in getting the public on board with gene patents. As 
has been displayed in the US, public opinion can influence the future of gene patents which 
became clear when viewing the amount of media coverage that the Myriad case attained. 
There is still a great distrust against the concept of owning genes which, at least in part, lead 
to the Myriad case. The case has gained great media coverage whereof some have criticized 
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the information being spread by news papers as being faulty and lacking in judicial 
correctness.194 When the US government sent in an amicus curiae brief it became apparent 
that this distrust permeates several levels of society. The media coverage appears to have 
spread greatly exclaiming that the Myriad test is both inefficient and costly.195 Media is 
naturally focused on gaining attention and may thus benefit from twisting the issue into 
something which will cause public stir. The discussion in the US does, however, clearly show 
that the issue of gene patents, especially in humans, is something which many tend to find 
difficult to accept from ethical, legal and humane perspectives.  
The Monsanto case was the first verdict after the biotechnical directive was presented. The 
fact that so many years have passed since the directive was implemented and the first ruling is 
in itself a reflection upon that the directive is merely a codification of rules which were 
already a reality in large parts of Europe via the EPO and national legislation. The case in 
itself is a slight limitation of what appears to be a very optimistic filing from Monsanto. It 
?????? ????? ??????????? ?????? ???????????? ?? ????? ???? ??????? ??? ???????????? ???? ??????
?????????????????????????????????????????????????????????????????????????????????????????.  The 
lesson to be learned from the case is that Monsanto had incentive to test the boundaries of 
gene patents and a wish to expand the scope of protection which, in combination, was what 
????? ??? ??????????????? ??????? ???????????? ??????????? ????????? ??? ??tably closed the door to 
extending gene patents not non-viable genes while the ECJ showed continuing support for the 
system of gene patents.  
In Sweden, and most EU member states, the theoretical scope of gene patents is extensive 
since the directive and national legislation supplies the ability to apply for absolute product 
protection. As has been mentioned above patent applications have diminished as a result of 
the ICOS case and the HGS project. The fact that this development of patent criteria has taken 
place in the administrative arena instead of the judicial may in itself be a problem. There are 
an extensive amount of considerations to take in while deciding on the future of gene patents 
which extend beyond the realm of financial incentives and which may thus been better 
processed by policy.  
The ethical perspectives will probably never stop being current in this debate which means 
that there is room for legislators to improve the system in order to reach an equilibrium 
between the social, financial and judicial. The Duke report shows that there are new 
                                                 
194 Morrisson, Biotechnology Law Report 2010 p. 609. 
195 See for instance Crichton, New York Times, 2007. 
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considerations to be made in order to optimize the patent system and at the same time the 
Myriad debate reflects the public interest in the issue. Rationalizing between the different 
levels of the law may allow the system to become more unilateral and balanced by 
incorporating more socio-political views.  One idea could be a system where the laws deep 
?????????? ??? ???????????? ??? ???????????? ????????? ?? ???????? ??????? ??? ????????????? ??????? ???
efficient health care or more efficient crops. This could be created by differentiating between 
the areas of gene patens which have been shown to not benefit from a generous patent system 
and apply an invention-based patent on those areas instead where the patent would be bound 
by a specific use and not incorporate the gene in all of its potential uses.  
The financial power is undoubtedly a very strong force yet the courts have developed towards 
more restrictive criteria on gene patent. As of now there are no suggested forms of 
differentiation between different types of gene patents or figures on what the cost would be to 
implement a system which is more dedicated towards being optimized at efficiency. What is 
clear today is that there is a very large benefit to be made for those companies who are able to 
secure a gene and this is even after the patent system has evolved towards being more 
restrictive.  
The problem remains that with the broad form of protection comes larger incentives to invest. 
This may, at first glance, appear to be positive and meet the aim of the legislation, however, in 
the cases discussed above it may also be the large financial incentive which drives the system 
to expand beyond what it was constructed for by for example perusing less ethical forms of 
gene therapy.  
It could be argued that if gene patents were no longer allowed and that the biotechnological 
industries would instead have to rely on patents on the final product that this would allow the 
legislator a larger amount of control over the ethical aspects of the development. This solution 
would also allow for the industry to gain protection on their end product but not of the gene 
itself. Naturally the biotechnical industry would argue that this protection would be 
inadequate in relation to the investments which are made. The question remains if this is 
completely true regarding all types of patents on genes. Could it instead be possible to 
separate genes into different categories and apply protection on the basis of what it most 
beneficial for that individual category? However, this could cause problems with regards to 
royalty stacking but it may be that the gain of creating a more segmented system for gene 
patents balances the complications which will be met.  
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It may be that not all categories of gene patents require the level of protection which is 
supplied today. It may be as the as the poem quoted in the beginning states, that we can find 
the best solution between the ???????? ???? ???? ??????? ??????? the future may hold the 
possibility of creating a more refined system which limits the scope of protection to the end 
product or to the entire gene, depending on what is most efficient while finding a balance 
between financial, and human interests.  
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Illustation of the amino acid pairs which make up a DNA double helix.  
 
 
 
